ABVD Brintoxinab

Graham: Does the RATL have any significance whatsoever if you are going to AAVD plus Brintoxinab? Graham: The bottom line is I don't think it does. We actually proposed doing a trial of a response adapted AAVD Brint toxin approach, but we never really stood a chance for it being funded. He says he would struggle to see a role for ABVD if that were available.